[1] |
Clark T, Maximin S, Meier J, et al.Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44:479-486.
|
[2] |
Kassahun WT.Contemporary management of fibrolamellar?hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol, 2016, 14:151.
|
[3] |
Zhang X, Li J, Shen F, et al.Significance of presence of microvascular invasion in specimens obtained after surgical treatment of?hepatocellular carcinoma. J Gastroenterol Hepatol, 2018, 33:347-354.
|
[4] |
Leite NC, Villela-Nogueira CA, Pannain VL, et al.Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int, 2011, 31:700-706.
|
[5] |
Serste T, Barrau V, Ozenne V, et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology, 2012, 55:800-806.
|
[6] |
Forner A, Vilana R, Ayuso C, et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology, 2008, 47:97-104.
|
[7] |
Kim TK, Lee KH, Jang HJ, et al.Analysis of gadobenate dimeglumineenhanced MR findings for characterizing small (1-2 cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology, 2011, 259:730-738.
|
[8] |
Leoni S, Piscaglia F, Golfieri R, et al.The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol, 2010, 105:599-609.
|
[9] |
European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015, 63:237-264.
|
[10] |
Mitchell DG, Bruix J, Sherman M, et al.LI-RADS (Liver imaging reporting and data system): summary, discussion, and consensus of the LIRADS Management Working Group and future directions. Hepatology, 2015, 61:1056-1065.
|
[11] |
Choi JY, Lee JM, Sirlin CB.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology, 2014, 273:30-50.
|
[12] |
王可, 孙少帅, 郭小超,等. 肝脏影像报告及数据系统2017 版(LI-RADS~v2017)解读.中国医学影像技术, 2017, 33:157-161.
|
[13] |
Zhang YD, Zhu FP, Xu X, et al.Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol,2016, 23:344-352.
|
[14] |
Zhang YD, Zhu FP, Xu X, et al.Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol, 2016, 23:344-352.
|
[15] |
Corwin MT, Fananapazir G, Jin M, et al.Differences in liver imaging and reporting data system categorization between MRI and CT. AJR, 2016, 206:307-312.
|